Taysha Gene Therapies Inc (NASDAQ:TSHA) has a beta value of 0.89 and has seen 2.13 million shares traded in the last trading session. The company, currently valued at $436.78M, closed the last trade at $2.13 per share which meant it gained $0.03 on the day or 1.43% during that session. The TSHA stock price is -102.82% off its 52-week high price of $4.32 and 50.7% above the 52-week low of $1.05.
The consensus among analysts is that Taysha Gene Therapies Inc (TSHA) is Buy stock at the moment, with a recommendation rating of 1.09. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 8 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight.
Taysha Gene Therapies Inc (NASDAQ:TSHA) trade information
Sporting 1.43% in the green in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the TSHA stock price touched $2.13 or saw a rise of 17.12%. Year-to-date, Taysha Gene Therapies Inc shares have moved 23.12%, while the 5-day performance has seen it change -17.44%. Over the past 30 days, the shares of Taysha Gene Therapies Inc (NASDAQ:TSHA) have changed 77.50%.
Wall Street analysts have a consensus price target for the stock at $8.5, which means that the shares’ value could jump 74.94% from current levels. The projected low price target is $5.0 while the price target rests at a high of $44.0. In that case, then, we find that the current price level is -1965.73% off the targeted high while a plunge would see the stock gain -134.74% from current levels.
Taysha Gene Therapies Inc (TSHA) estimates and forecasts
The company’s shares have gained 67.72% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -63.99% over the past 5 years. Earnings growth for 2025 is a modest 3.49% while over the next 5 years, the company’s earnings are expected to increase by 8.17%.
TSHA Dividends
Taysha Gene Therapies Inc is expected to release its next earnings report in June this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Taysha Gene Therapies Inc (NASDAQ:TSHA)’s Major holders
The top two institutional holders are FMR LLC with over 21.21 million shares worth more than $47.51 million. As of 2024-06-30, FMR LLC held 9.1103% of shares outstanding.
The other major institutional holder is RTW INVESTMENTS, LP, with the holding of over 18.8 million shares as of 2024-06-30. The firm’s total holdings are worth over $42.11 million and represent 8.075% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . As of Dec 31, 2024 , the former fund manager holds about 2.36% shares in the company for having 4.85 shares of worth $10.33 million while later fund manager owns 4.58 shares of worth $9.76 million as of Mar 31, 2025 , which makes it owner of about 2.23% of company’s outstanding stock.
